Welcome to MOLOGEN AG

Our research - for you. That means, we conduct research to develop highly effective drugs with few side effects and excellent tolerability. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

3 Questions to Dr. Söhngen

DR. MARIOLA SÖHNGEN CEO MOLOGEN AG

• The focus of the activities continued to be on the lead product lefitolimod (MGN1703) • Advances in the IMPALA pivotal study and expansion of the TEACH study • Cooperation agreement with MD Anderson Cancer Center regarding a combination study with checkpoint inhibitors • Annual General Meeting in August • Forecast for the... [more]

MOLOGEN AG announces that the United States Patent and Trademark Office (PTO) has declared that it will grant a patent (Notice of Allowance) for the combined use of the lead product, immunotherapy MGN1703, with a chemotherapeutic agent. [more]

Quarterly Statement as at 31 March 2016
Download PDF

Annual Report 2015
Download PDF